The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 21, 2024

Filed:

Aug. 30, 2019
Applicant:

Nanjing Sanhome Pharmaceutical Co., Ltd., Jiangsu, CN;

Inventors:

Yong Wang, Jiangsu, CN;

Liwen Zhao, Jiangsu, CN;

Qifeng Song, Jiangsu, CN;

Yongqiang Zhu, Jiangsu, CN;

Yanan Zhang, Jiangsu, CN;

Luwei Han, Jiangsu, CN;

Liang Jin, Jiangsu, CN;

Wenming Wu, Jiangsu, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to the technical field of antibody drugs, and in particular, to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the anti-CD47 antibody or the antigen-binding fragment thereof, and applications thereof. The anti-CD47 antibody or the antigen-binding fragment thereof has significant antitumor activity and high affinity with human CD47 protein, can eliminate the capability of SIRPa to bind to CD47 on a surface of a cell, and does not have significant hemoagglutination activity and thus can be applied to the preparation of an anti-tumor drug.


Find Patent Forward Citations

Loading…